Trend analysis as per recent USFDA guideline [Bioanalytics]

posted by dshah  – India, 2020-08-01 09:32 (1564 d 11:50 ago) – Posting: # 21815
Views: 7,711

Dear All!

If we consider the recent FDA guideline or ICH M10, i believe trend analysis for IS response, CC and QCs is also required. FDA does ask if there is upward or downward trend observed. The important point for SOP of CRO should be - allowed limit for IS response. If this not limited for that 3 subjects, then i believe CRO's practice and SOP needs to be revised.

Regards,
Dshah


Edit: Guidelines linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,297 posts in 4,892 threads, 1,675 registered users;
82 visitors (0 registered, 82 guests [including 18 identified bots]).
Forum time: 20:22 CET (Europe/Vienna)

Science… never solves a problem
without creating ten more.    George Bernard Shaw

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5